NASDAQ:SANA - Sana Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 100.80 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$19.92
▼ -0.6 (-2.92%)

This chart shows the closing price for SANA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sana Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SANA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SANA

Analyst Price Target is $40.00
▲ +100.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sana Biotechnology in the last 3 months. The average price target is $40.00, with a high forecast of $45.00 and a low forecast of $35.00. The average price target represents a 100.80% upside from the last price of $19.92.

This chart shows the closing price for SANA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Sana Biotechnology.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$35.00Low
3/1/2021Morgan StanleyInitiated CoverageOverweight$40.00Low
3/1/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00Low
3/1/2021Bank of AmericaInitiated CoverageBuy$45.00Low
(Data available from 6/23/2016 forward)
Sana Biotechnology logo
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $19.92
Low: $19.36
High: $20.78

50 Day Range

MA: $21.80
Low: $16.65
High: $25.98

52 Week Range

Now: $19.92
Low: $16.28
High: $44.60

Volume

318,475 shs

Average Volume

539,936 shs

Market Capitalization

$3.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sana Biotechnology?

The following Wall Street research analysts have issued stock ratings on Sana Biotechnology in the last year: Bank of America Co., JPMorgan Chase & Co., Morgan Stanley, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for SANA.

What is the current price target for Sana Biotechnology?

4 Wall Street analysts have set twelve-month price targets for Sana Biotechnology in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 100.8%. Bank of America Co. has the highest price target set, predicting SANA will reach $45.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $35.00 for Sana Biotechnology in the next year.
View the latest price targets for SANA.

What is the current consensus analyst rating for Sana Biotechnology?

Sana Biotechnology currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SANA will outperform the market and that investors should add to their positions of Sana Biotechnology.
View the latest ratings for SANA.

What other companies compete with Sana Biotechnology?

How do I contact Sana Biotechnology's investor relations team?

Sana Biotechnology's physical mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The company's listed phone number is 206 701 7914 and its investor relations email address is [email protected] The official website for Sana Biotechnology is sana.com.